Information Provided By:
Fly News Breaks for November 20, 2018
NVTA
Nov 20, 2018 | 06:51 EDT
Benchmark analyst Bruce Jackson assumed coverage of Invitae with a Buy rating and $17 price target. The analyst sees the company's growth in 2019 being driven by expansion into the obstetrics/gynecology market, supported by non-invasive prenatal testing and expanded carrier screening. Invitae aims to be the market leader in genetic testing, says the analyst.
News For NVTA From the Last 2 Days
There are no results for your query NVTA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.